Gene therapy · Gene replacement · developed by Krystal Biotech
KB803 is an ophthalmic suspension of a replication-defective, non-integrating herpes simplex virus type 1 vector that expresses the human collagen VII protein. It is being studied in dystrophic epidermolysis bullosa.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07016750 | Phase 3 | Dystrophic Epidermolysis Bullosa | Recruiting | KRYS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
DEB - Dystrophic Epidermolysis BullosaDominant Dystrophic Epidermolysis BullosaDystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis Bullosa
Updated Oct 18, 2026. Something wrong or missing? Report it on the KRYS page.
See KRYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KRYS catalysts and pipeline →